Medexus Pharmaceuticals (MDP) Competitors

Medexus Pharmaceuticals (TSE:MDP) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.

Is MDP or OGI more profitable?

Medexus Pharmaceuticals has a net margin of 3.25% compared to Organigram's net margin of -31.69%. Medexus Pharmaceuticals' return on equity of 11.07% beat Organigram's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	3.25%	11.07%	4.89%
Organigram	-31.69%	-17.59%	-5.56%

Does the MarketBeat Community prefer MDP or OGI?

Organigram received 39 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Medexus Pharmaceuticals an outperform vote while only 44.95% of users gave Organigram an outperform vote.

Company	Underperform	Outperform
Medexus Pharmaceuticals	Outperform Votes 10 71.43%	Underperform Votes 4 28.57%
Organigram	Outperform Votes 49 44.95%	Underperform Votes 60 55.05%

Do institutionals and insiders believe in MDP or OGI?

8.3% of Medexus Pharmaceuticals shares are held by institutional investors. Comparatively, 8.4% of Organigram shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Comparatively, 31.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has better earnings & valuation, MDP or OGI?

Medexus Pharmaceuticals has higher earnings, but lower revenue than Organigram. Organigram is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$100.25M	0.65	C$3.26M	C$0.21	14.01
Organigram	C$180.58M	1.36	-C$57.23M	-C$0.47	-4.21

Does the media prefer MDP or OGI?

In the previous week, Organigram had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 1 mentions for Organigram and 0 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score.

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Organigram	Neutral

Do analysts recommend MDP or OGI?

Medexus Pharmaceuticals currently has a consensus price target of C$5.49, indicating a potential upside of 87.29%. Organigram has a consensus price target of C$3.33, indicating a potential upside of 67.09%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	4 Strong Buy rating(s)	3.29
Organigram	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, MDP or OGI?

Medexus Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Summary

Medexus Pharmaceuticals beats Organigram on 11 of the 17 factors compared between the two stocks.